Curative Biotechnology Stock Current Ratio
| CUBT Stock | USD 0.01 0.0001 1.15% |
Curative Biotechnology fundamentals help investors to digest information that contributes to Curative Biotechnology's financial success or failures. It also enables traders to predict the movement of Curative Stock. The fundamental analysis module provides a way to measure Curative Biotechnology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Curative Biotechnology stock.
| Last Reported | Projected for Next Year | ||
| Current Ratio | 0.11 | 0.10 |
Curative | Current Ratio |
Curative Biotechnology Company Current Ratio Analysis
Curative Biotechnology's Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Current Curative Biotechnology Current Ratio | 0.10 X |
Most of Curative Biotechnology's fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Curative Biotechnology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Curative Current Ratio Driver Correlations
Understanding the fundamental principles of building solid financial models for Curative Biotechnology is extremely important. It helps to project a fair market value of Curative Stock properly, considering its historical fundamentals such as Current Ratio. Since Curative Biotechnology's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Curative Biotechnology's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Curative Biotechnology's interrelated accounts and indicators.
Click cells to compare fundamentals
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
| Competition |
Curative Price To Sales Ratio
Price To Sales Ratio |
|
In accordance with the recently published financial statements, Curative Biotechnology has a Current Ratio of 0.1 times. This is 96.56% lower than that of the Biotechnology sector and 98.57% lower than that of the Health Care industry. The current ratio for all United States stocks is 95.37% higher than that of the company.
Curative Current Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Curative Biotechnology's direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Curative Biotechnology could also be used in its relative valuation, which is a method of valuing Curative Biotechnology by comparing valuation metrics of similar companies.Curative Biotechnology is currently under evaluation in current ratio category among its peers.
Curative Biotechnology Current Valuation Drivers
We derive many important indicators used in calculating different scores of Curative Biotechnology from analyzing Curative Biotechnology's financial statements. These drivers represent accounts that assess Curative Biotechnology's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Curative Biotechnology's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 726.3K | 9.9M | 26.1M | 11.4M | 14.1M | 14.8M | |
| Enterprise Value | 726.4K | 10.3M | 25.4M | 12.5M | 16.3M | 17.1M |
Curative Fundamentals
| Return On Equity | -3.98 | ||||
| Return On Asset | -0.52 | ||||
| Current Valuation | 10.3 M | ||||
| Shares Outstanding | 903.26 M | ||||
| Shares Owned By Insiders | 0.05 % | ||||
| Price To Sales | 158.53 X | ||||
| Revenue | 132.32 K | ||||
| Gross Profit | 100.21 K | ||||
| EBITDA | (2.5 M) | ||||
| Net Income | (3.96 M) | ||||
| Cash And Equivalents | 126.85 K | ||||
| Total Debt | 2.26 M | ||||
| Debt To Equity | 6.60 % | ||||
| Current Ratio | 0.10 X | ||||
| Book Value Per Share | (0) X | ||||
| Cash Flow From Operations | (486.58 K) | ||||
| Earnings Per Share | (0.01) X | ||||
| Beta | 214.95 | ||||
| Market Capitalization | 9.03 M | ||||
| Total Asset | 2.6 M | ||||
| Retained Earnings | (38.23 M) | ||||
| Working Capital | (4.42 M) | ||||
| Net Asset | 2.6 M |
About Curative Biotechnology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Curative Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Curative Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Curative Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Curative Stock Analysis
When running Curative Biotechnology's price analysis, check to measure Curative Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Curative Biotechnology is operating at the current time. Most of Curative Biotechnology's value examination focuses on studying past and present price action to predict the probability of Curative Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Curative Biotechnology's price. Additionally, you may evaluate how the addition of Curative Biotechnology to your portfolios can decrease your overall portfolio volatility.